Background. Elevated levels of cholesterol and apoprotein B (apo B), the essential carrier protein for low density lipoprotein, are major lipid risk factors for premature coronary disease. Antiarrhythmic agents are frequently prescribed to patients with coronary heart disease and associated cardiac arrhythmias. As part of another study, we retrospectively investigated the effect of antiarrhythmic agents on blood lipids.
G uidelines developed by the National Cholesterol Education Program's Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults' identified elevated cholesterol and low density lipoprotein cholesterol (LDL C) concentrations as the major targets for cholesterol-lowering therapy. The importance of cholesterol reduction in patients with overtly manifest coronary artery disease cannot be overstated, because virtually every major epidemiological study performed to date has shown a significant correlation between the level of serum cholesterol at the time of entry and the risk of subsequent coronary disease. 2 The results of 22 randomized cholesterol-lowering clinical trials to reduce the risk of coronary heart disease indicate an average reduction of 23% in the risk of nonfatal myocardial infarction and cardiac death in treated compared with control patients.3 In particular, a with a reduction of approximately 20% in the incidence of new coronary events. 3 Present therapeutic guidelines include the recommendation that cholesterol-lowering drugs should be considered when cholesterol and LDL C levels remain significantly elevated after 6 
Methods

Study Population
The study population consisted of 1,567 survivors of the original cohort of 2,466 postinfarction patients enrolled in the MDPIT on whom lipid and lipoprotein specimens were obtained at study termination. The details of patient recruitment, data acquisition, data management, and follow-up have been previously reported.8 Patients were randomly assigned to diltiazem or placebo and were followed at periodic intervals throughout the trial. All patients were followed for at least 12 months, to a maximum of 52 months; the average duration of follow-up was 25 months.
Blood Samples for Lipids
Venous blood was collected at enrollment before randomization to diltiazem trial medication (3-15 days after onset of the myocardial infarction), at approximately 6 months after entry into the study (range, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] months), and as part of the closeout procedure at study termination (average, 30 months). An 
Medication Usage
The cardiac medications that the patients were receiving were identified at baseline, at each follow-up contact, and at closeout by using a prespecified medication dictionary. The medication categories included antiarrhythmic agents, ,B-blockers, digitalis preparations, diuretic agents, nitrates other than sublingual preparations, and the trial medication (diltiazem or placebo). Each category was subcategorized for specific agents. At closeout, 76 patients were on type Ta antiarrhythmic medication: 41 were on quinidine (mean daily dose, 964 mg); 29 were on procainamide (mean daily dose, 2,578 mg); and six were on disopyramide (mean daily dose, 367 mg). More than 90% of patients on type Ia agents at closeout were receiving these medications for 90 days or longer. Twenty-seven patients were on a variety of other type I antiarrhythmic agents (21 on type lb and six on type Ic), and these agents had no apparent effect on serum lipids. No patient was on moricizine.
Statistical Analyses
The difference in the group mean values of cholesterol, HDL C, triglycerides, apo A-I, apo A-II, apo B by RIA, and apo B by RID for patients receiving and not receiving type Ia antiarrhythmic agents was evaluated by the two-sample t test. Multiple linear regression analyses (BMDP-2Rl6) were performed on the closeout blood samples to identify baseline demographic, clinical, and closeout therapeutic covariates that influence the serum lipid levels. A separate regression model was developed for the logarithm of each lipid fraction. The log transformation was taken to reduce skewness in the response variables. Relevant covariates were selected by a stepwise procedure (F.4.0) from the dichotomized variables listed in Table 1 . The covariates used in the selection process involved age, sex, previous myocardial infarction, New York Heart Association class, history of treated hypertension, coronary bypass surgery, diabetes, cigarette smoking, shock, rales, pulmonary congestion by x-ray, creatine kinase level, blood urea nitrogen, blood pressure, anterolateral Q wave, inferior posterior Q wave, non-Q wave, ejection fraction, heart rate, ventricular ectopics, ventricular runs, diltiazem, ,3-blocker, digitalis, diuretics, and nitrates. Antiarrhythmic medication was then added to the model to evaluate on HDL C, and apo A-I levels were only slightly lower (6% lower; p=0.02) in those using than those not using type Ta agents. The magnitude of the lipid-lowering effect with type Ta antiarrhythmic agents on serum total cholesterol was approximately 9%.
It should be emphasized that in this postinfarction population, patients were not selected for enrollment into the diltiazem study according to any specific inclusion or exclusion criteria for blood lipids. The level of total cholesterol observed in this otherwise unselected postinfarction population was only minimally elevated. For example, the mean total cholesterol for the 1,491 patients not receiving type Ta antiarrhythmic therapy at study closeout was 228+±47 mg/dl-a value that would be considered "borderline high" (200-239 mg/dl) by the National Cholesterol Education Program.'
It should be pointed out that in this and other postinfarction studies,'7 cholesterol levels are lowest during the hospital phase of acute myocardial infarction and then progressively increase during posthospital convalescence. We observed a 9-11% lower cholesterol level in patients receiving than not receiving type Ta antiarrhythmic agents at three different times after the index infarction (Table 2) . This cross-sectional observation is different from the longitudinal reduction in cholesterol from a stable baseline value reported in randomized, double-blind, placebo-controlled clinical trials with standard hypolipidemic agents.'8 For example, in the Lipid Research Clinics Primary Prevention Trial,'9 cholestyramine was associated with a 13% reduction in cholesterol from baseline. It is interesting that the magnitude of the cholesterol reduction with cholestyramine is similar to the 9-11% lower cholesterol that we observed in patients using type Ia agents compared with patients not on these medications.
LDL, the major cholesterol-carrying particle in serum, has a lipid core and a single surface apoprotein, apo B-100. 20 An elevated level of LDL C is a major risk factor for the premature development of coronary atherosclerotic disease, and there is considerable interest in lowering LDL C by diet and medication. LDL C is usually computed by the Friedewald formula2' from directly measured total cholesterol, HDL C, and triglyceride values. The accuracy of this computation assumes a fasting blood sample and a fixed ratio of triglyceride to cholesterol in the triglyceride-rich lipoprotein moieties.
We calculated the LDL C concentrations but did not report the findings in the "Results" section because all blood samples were not drawn in the fasting state and because of potential inaccuracies in the Friedewald assumptions. Despite these reservations, the calculated LDL C level was significantly (p=0.003) lower among those receiving type la antiarrhythmic agents (LDL C= 127+47 mg/dl) than those not on these medications (LDL C=145±45 mg/dl) at closeout. This computed 12% lower LDL C level is internally consistent with the independently measured 13% lower apo B level. The mechanism of the hypolipidemic effect of type Ta antiarrhythmic agents is uncertain. Apo B is the essential carrier protein for LDL. 20 The lower apo B, triglyceride, and LDL C levels in patients using versus patients not using type Ia antiarrhythmic agents may be due to type la agent inhibition of hepatocyte apo B synthesis, reduction of triglyceride-rich very low density lipoprotein (VLDL) secretion by liver parenchymal cells (apo B-100 is an important component of VLDL, a major precursor of LDL20), enhancement of LDL clearance by its receptor, or combinations of these mechanisms. It is known that VLDL secretion is inhibited by agents that alter hepatic transmembrane ionic gradients.22 Type Ta antiarrhythmic agents exert their cardiac electrophysiological effect primarily through reduction in sodium conductance across the myocellular membrane. These agents surely affect other cells in the body, as well. It is interesting to speculate that type la agents may inhibit hepatocyte VLDL secretion by pharmacologically altering the flux of ions across hepatocellular membranes. A sustained reduction in VLDL secretion could produce secondary reductions in the levels of apo B, triglycerides, and LDL C. It is interesting that the approved hypolipidemic agent probucol and type Ia antiarrhythmic agents have similar electrophysiological effects on heart muscle, i.e., QT prolongation.5.23 It may be that type Ta agents lower lipid levels by the same mechanism as probucol does, i.e., through similar effects on hepatocellular ionic currents.
Type la agents also lowered the concentration of apo A-TI but had no apparent effect on HDL C concentration ( ables. Even after adjustment, the cholesterol, triglyceride, apo A-TI, and apo B levels were significantly (p<0.001) lower in those using type Ia agents than in those not on these medications. In this observational study, the nonrandomness of how patients were selected for antiarrhythmic therapy may have introduced unsuspected bias. We cannot adjust for covariates that were not measured. For example, we did not have information on which patients were in a fasting state when the blood samples were drawn. It is possible there was some imbalance in the distribution of fasting and nonfasting specimens between those using and not using type Ta agents that could bias the results. It should be noted that at closeout (30 months after infarction) the average weight of patients receiving type Ta antiarrhythmic agents was similar to those not on these agents -a finding that rules against a major disparity in diet, caloric intake, and cardiac cachexia between the two groups.
The blood samples were collected prospectively as part of the original study protocol. 8 The lipid determinations were obtained at baseline, at 6 months, and 30 months after infarction, with consistently lower lipid levels in patients using type la agents at all three time periods. All specimens were analyzed in blinded fashion at a core lipid research laboratory that had no preexisting knowledge of any clinical or laboratory information during the conduct of the trial that could have in any way biased the results of the current analysis.
In summary, this study shows that patients on type Ia antiarrhythmic medications had significantly lower cholesterol, triglyceride, apo A-TI, and apo B levels than patients not on these medications. These lipid-lowering effects were independent of age, sex, body weight, diabetes, smoking status, concomitant medications, and a variety of measured covariates relating to the severity of the coronary disease process. These data suggest that type Ia antiarrhythmic agents may represent a new class of hypolipidemic agents. The mechanism of these effects is undefined. Additional investigation will be necessary to further clarify the potential role of such pharmacological agents in cholesterol-lowering therapy.
